Overview of the global glaucoma therapeutics market
Technavio’s market research report has identified the advent of new innovative combination drugs to be one of the primary factors driving the growth of the glaucoma therapeutics market till 2021. To control the elevated intraocular pressure (IOP), healthcare physicians recommend a combination of two or more drugs for about 40%-45% of the glaucoma patients. According to clinical studies , the prescription of fixed combination therapies for glaucoma is more effective in lowering IOP than individual therapeutic agents. Moreover, the prescription of fixed combination also simplifies the medical regimen. Cosopt (timolol/dorzolamide), combigan (timolol/brimonidine), xalacom (timolol/latanoprost), ganfort (timolol/bimatoprost), and duotrav (timolol/travoprost) are the common combination drugs used for glaucoma. Technavio’s market research analysts estimate that this market will register a revenue of more than USD 8 billion by 2021.
The emergence of new drug delivery techniques such as the adoption of various strategies to provide the drug with a carrier to hold the drug on the surface of the cornea for a longer duration benefits patients by reducing the frequency of doses. This will in turn, improve the patients’ adherence and compliance to the medication. According to our market research analysts, the emergence of new drug delivery methods will be one of the key trends that will gain traction in the glaucoma therapeutics market during the next few years.
Competitive landscape and key vendors
The glaucoma therapeutics market is characterized by the presence of key companies and the vendors compete against each other mainly based on factors such as product efficacy, prolonged action, limited side effects, rich pipeline, and operational base. The players in this marketspace are increasingly focusing on launching novel therapies and are investing heavily in R&D activities to improve their market positions.
Key vendors in this market are -
Other prominent vendors in the market include Bayer HealthCare, Akorn, Bausch & Lomb, Santen Pharmaceutical, Teva Pharmaceutical, and VISTAKON.
Segmentation by drug class and analysis of the glaucoma therapeutics market
Carbonic anhydrase inhibitors
The prostaglandin analogs segment accounted for the majr shares of the glaucoma therapeutics market during 2016. Prostaglandin analogs are extensively adopted for the treatment of open-angle glaucoma since they are more effective than the other drugs. Latanoprost, bimatoprost, travoprost, and tafluprost are the four prostaglandin analogs that are available in the market for the treatment of glaucoma. It has been observed that the administration of tafluprost, travoprost, and latanoprost has shown an IOP-lowering ability of 25%-32% during clinical trials. Similarly, bimatoprost showed IOP-lowering ability of 27%-32%.
Segmentation by geography and analysis of the glaucoma therapeutics market
The consumption of glaucoma drugs in the Americas is increasing due to the rising incidence of glaucoma in countries such as the US. Owing to its heavy investments in the healthcare sector, the US the major revenue contributor to the glaucoma therapeutics market in this region. With the presence of pharmaceutical giants and huge investments in the pharmaceutical industry, the need for glaucoma therapeutics will increase in the region during the predicted period.
Key questions answered in the report include
What will the glaucoma therapeutics market size and the growth rate be in 2021?
What are the key factors driving the global glaucoma therapeutics market?
What are the key glaucoma therapeutics market trends impacting the growth of the market?
What are the challenges to market growth?
Who are the key vendors in the global glaucoma therapeutics market?
What are the market opportunities and threats faced by the vendors in the global glaucoma therapeutics market?
What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
What are the key outcomes of the five forces analysis of the global glaucoma therapeutics market?
Technavio also offers customization on reports based on specific client requirement.